Equities Analysts Set Expectations for Henry Schein, Inc.’s Q2 2025 Earnings (NASDAQ:HSIC)

Henry Schein, Inc. (NASDAQ:HSIC) – Stock analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for shares of Henry Schein in a research report issued on Tuesday, April 16th. Zacks Research analyst U. Biswas now forecasts that the company will post earnings per share of $1.27 for the quarter, up from their prior forecast of $1.26. The consensus estimate for Henry Schein’s current full-year earnings is $5.07 per share.

A number of other brokerages also recently issued reports on HSIC. Jefferies Financial Group raised their price objective on Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a research report on Wednesday, March 6th. SVB Leerink initiated coverage on Henry Schein in a research report on Monday, February 26th. They set a “market perform” rating and a $78.00 price objective for the company. Evercore ISI raised their price objective on Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a research report on Wednesday, February 28th. Barrington Research raised their price objective on Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 28th. Finally, Piper Sandler raised their price objective on Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $81.09.

Henry Schein Stock Down 0.3 %

Shares of HSIC opened at $69.97 on Thursday. The stock has a fifty day simple moving average of $74.43 and a two-hundred day simple moving average of $72.48. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $8.99 billion, a PE ratio of 22.21, a price-to-earnings-growth ratio of 1.76 and a beta of 0.87. Henry Schein has a 52-week low of $60.01 and a 52-week high of $85.39.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The company had revenue of $3.02 billion during the quarter, compared to analyst estimates of $3 billion. During the same period last year, the business earned $1.21 earnings per share. The firm’s revenue was down 10.5% compared to the same quarter last year.

Insider Activity at Henry Schein

In related news, CEO Bradford C. Connett sold 6,430 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the transaction, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Bradford C. Connett sold 6,430 shares of Henry Schein stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the completion of the transaction, the chief executive officer now owns 73,108 shares in the company, valued at approximately $5,430,462.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of Henry Schein stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now owns 209,562 shares of the company’s stock, valued at approximately $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Henry Schein

Several institutional investors have recently added to or reduced their stakes in the business. Boston Partners increased its position in Henry Schein by 144.1% during the fourth quarter. Boston Partners now owns 2,637,429 shares of the company’s stock worth $199,393,000 after buying an additional 1,556,831 shares during the period. Norges Bank acquired a new position in Henry Schein during the fourth quarter worth approximately $111,715,000. Morgan Stanley increased its position in Henry Schein by 143.4% during the fourth quarter. Morgan Stanley now owns 2,337,890 shares of the company’s stock worth $186,727,000 after buying an additional 1,377,207 shares during the period. Nuance Investments LLC acquired a new position in Henry Schein during the fourth quarter worth approximately $103,446,000. Finally, Lazard Asset Management LLC increased its position in Henry Schein by 1,303.3% during the third quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company’s stock worth $92,614,000 after buying an additional 1,158,451 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.